Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate

To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.

Inclusion Criteria:Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consentMales ≥ 18 yearsHistologic diagnosis of adenocarcinoma of the prostate (PCa)Planned radical prostatectomy within the study periodTestosterone >150ng/mlAdequate organ function, defined as follows: Result DateLeukocytes >1.5K/ULAbsolute Neutrophil Count >1.5K/ULNOTE: Patients with established diagnosis of benign neutropenia are eligible to participate with ANC between 1000-1500 if in the opinion of treating physician the trial treatment does not pose excessive risk of infection to the patient.Platelets >100K/ULHemoglobin ≥ 9 g/dLSerum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault equationTotal bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ 1 x ULNAspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULNMen with partners of child-bearing potential must agree to practice sexual abstinence or to use the forms of contraception listed in Child-Bearing Potential/Pregnancy section for the duration of study participation. Men of child-bearing potential must not father a child or donate sperm while receiving investigational treatment. Following treatment (standard of care prostatectomy) there is no further child-bearing potential.Exclusion Criteria:Current or recent (within 6 months) use of testosterone/estrogen modulating agents (leuprolide, degarelix, bicalutamide, enzalutamide, apalutamide, darolutamide, abiraterone, systemic ketoconazole, tamoxifen, etc)Current use of CYP3A4 inhibitorsSubjects using the following medications within 2 weeks prior to first dosing (or within 5 times the half-life of that medication, whichever is longer) will be excluded from the study:Inhibitors of CYP3A4 (including but not limited to macrolide antibiotics, HIV protease inhibitor, azole antifungal drugs, cyclosporine, calcium channel inhibitor, cimetidine)Inducers of CYP3A4 (including but not limited to rifampicin, carbamazepine, efavirenz, bosentan, modafinil, St. John's Wort), Medications with narrow therapeutic index that are metabolized CYP3A4 and/or CYP2D6 are not allowed from screening until up to 5 half-lives after last dose of Osanetant is administered.Cognitive impairment (defined as the presence of diagnosed dementia)Impaired renal function: Cr >1.8Medical history of osteoporosisCurrent systemic corticosteroid, long-term opioid, spironolactone, or eplerenone useHas a known allergic reaction to any excipient contained in the study drug formulationActive Grade 3 (per the NCI CTCAE, Version 5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment.Active COVID-19 infectionAny history of underlying liver disorder, including hepatitis (see below)Any evidence of acute or chronic hepatitis B or C on screening testingElevation of any or all liver enzymes (ALT, AST, total bilirubin) above the upper limit of normal (ULN) at baseline testing prior to enrollmentA family history of hepatitis or currently living with a person who has been given a diagnosis of hepatitisA history of or currently working as a sex workerA history of or currently using intravenous (IV) drugsA self-reported history of alcoholic dependency or abuseA history of or current diagnosis of cardiovascular disease including heart failure, coronary artery disease, uncontrolled hypertension, uncontrolled diabetes; arrhythmias (or history of), or clinically relevant ECG abnormalities at baseline